- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
SGLT-2 Inhibitor and GLP-1 Receptor Agonist Prescribing Trends 2015-2020
PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.
Primary care physicians (PCPs) and internists prescribed more than half of all sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) dispensed in 2020, according to research on trends published by a team from the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins School of Medicine.
The study was originally designed to asses uptake over time of the cardioprotective agents by cardiologitsts and compared use by those specialists with that by endocrinologists, nephrologists, PCPs/interists, and advanced practice providers (APP) from 2015 to 2020.
There is significant discussion currently around percieved "less than optimal" use of both classes, given labeling that makes them appropriate for a broad range of patients wtih cardiometabolic disease.
Following is a top-line look at what the study found. Where do you net out on prescribing for your patients?
